We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study.
- Authors
Brandes, Alba A.; Ermani, Mario; Basso, Umberto; Paris, Myriam K.; Lumachi, Franco; Berti, Franco; Amistà, Pietro; Gardiman, Marina; Iuzzolino, Paolo; Turazzi, Sergio; Monfardini, Silvio
- Abstract
Objectives: To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine. Methods: Forty-two patients with GBM were administered TMZ at the dose of 150 mg/m[sup 2] /daily for 5 days every 4 weeks. Results: The PFS-6 and at 12 months (PFS-12) was 24% (95% Confidence Interval [CI] = 14–42%) and 8% (CI = 2–27%), respectively, with a median TTP of 11.7 weeks (CI = 9–22 weeks). The response was assessed in all 42 patients; we observed 2 complete responses (CR) (4.7%), 6 partial responses (PR) (14.3%), and 9 stable disease (SD) (21.4%), with CR+PR = 19% (CI = 7–31%). Conclusion: TMZ as a second line regimen is a valid option in patients with heavily pretreated GBM.Copyright © 2002 S. Karger AG, Basel
- Subjects
BRAIN tumors; GLIOBLASTOMA multiforme; DRUG therapy; RADIOTHERAPY; ONCOLOGIC surgery
- Publication
Oncology, 2002, Vol 63, Issue 1, p38
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000065718